Skip to main content

Table 6 Baseline biochemical parameters in adult patients

From: The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics

Parameter rhPTH(1-84)
(n=125)
Conventional therapy
(n=571)
Analysis populationa
(N=696)
n Value n Value n Value
Total serum calcium, mmol/L
 Mean ± SD 83 2.2±0.34 489 2.2±0.21 572 2.2±0.24
 Median (range)   2.2 (1.30–3.53)   2.2 (1.15–3.15)   2.2 (1.15–3.53)
Serum phosphateb, mmol/L
 Mean ± SD 53 1.3±0.27 280 1.4±0.26 333 1.4±0.26
 Median (range)   1.3 (0.8–1.9)   1.3 (0.7–2.1)   1.3 (0.7–2.1)
Serum creatinine, μmol/L
 Mean ± SD 69 86.9±55.93 452 84.1±30.80 521 84.5±35.11
 Median (range)   74.3 (38.9–479.1)   78.3 (26.5–284.6)   77.8 (26.5–479.1)
eGFR, mL/min/1.73 m2
 Mean ± SD 69 83.2±23.73 454 80.2±24.34 523 80.6±24.25
 Median (range)   84.9 (8.2–128.5)   81.1 (0.5–162.5)   81.4 (0.5–162.5)
  1. eGFR estimated glomerular filtration rate, rhPTH(1-84) recombinant human parathyroid hormone (1-84)
  2. aBaseline is defined as the assessment at enrollment (visit 1). The baseline measurement was the most recent value before the first dose in patients receiving treatment with rhPTH(1-84); pediatric patients (n=27), those who received rhPTH(1-34) (n=14), and those with outlier data for total serum calcium <0.88 mmol/L, >5.00 mmol/L (<3.5 mg/dL, >20.0 mg/dL); serum phosphate <0.32 mmol/L, >2.58 mmol/L (<1.0 mg/dL, >8.0 mg/dL); serum creatinine <17.68 μmol/L, >884.00 μmol/L (<0.2 mg/dL, >10.0 mg/dL); eGFR no lower limit/except negative values excluded, >200.0 mL/min/1.73 m2, were excluded from the analysis
  3. bInorganic phosphate was measured